Stallergenes: playing a part in the desensitization market transition

• Strong growth supporting major investment in R&D

• 13 clinical trials, 5,000 patients included in the stalair® programme

• Industrial investment that meets EMEA and FDA standards

• A development programme in line with clinical and regulatory requirements

• Dynamic high potential personnel recruitment policy